Who manufactures Enflonsia (Clesrovimab)?

Clesrovimab-cfor bulk supplier for pharma manufacturers

Clesrovimab-Cfor 105 mg Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 105 mg

Reference Brands: Enflonsia (USA)

Clesrovimab-cfor is a long-acting monoclonal antibody directed against the fusion (F) protein of Respiratory Syncytial Virus (RSV), designed for passive immunization of neonates and infants during or entering their first RSV season. It binds a conserved epitope on the RSV F protein, thereby preventing viral entry, and is given as a single-dose IM injection providing protection throughout a typical 5-month RSV season.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Clesrovimab-Cfor? List it or send an offer →

Product Description:

Clesrovimab is a long-acting monoclonal antibody against the fusion protein of respiratory syncytial virus. It binds the prefusion form of the protein and prevents the virus fusing with and entering airway cells. It is not a vaccine: it supplies ready-made antibody, so protection starts immediately rather than waiting for an immune response — which matters for newborns entering their first RSV season.

It is used to prevent RSV lower respiratory tract disease in infants born during or entering their first RSV season, as a single intramuscular dose, at the same dose regardless of weight. RSV is the leading cause of infant hospitalisation worldwide, and immunisation of infants with long-acting antibodies has changed hospitalisation rates in the countries that have adopted it. Injection site reactions and rash are the common adverse effects. Hypersensitivity reactions are recognised.

Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain. This is a seasonal public-health product: demand is concentrated in the months before the RSV season, purchasing is usually national immunisation programme rather than commercial, and supply must be committed well ahead. It competes with another long-acting RSV antibody and with maternal vaccination.

How Clesrovimab-Cfor is supplied today, and licensing ahead of patent expiry

Clesrovimab-Cfor is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Clesrovimab-Cfor, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Clesrovimab-Cfor supply →

Back to Listing

Frequently Asked Questions

Enflonsia (Clesrovimab) is developed and sold by Merck & Co (MSD). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.